Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists, announced the appointment of Suresh Durgam, M.D., to its board of directors, subject to approval by Cboe Canada. Durgam previously served on the company's scientific advisory board and brings more than 20 years of experience in central nervous system drug development, clinical research, and regulatory strategy.
Durgam's most recent role was executive vice president and chief medical officer of Intra-Cellular Therapies, where he helped secure U.S. Food and Drug Administration approvals for CAPLYTA across multiple indications, including schizophrenia, bipolar depression, and major depressive disorder. His deep expertise in navigating the regulatory landscape and bringing CNS therapies to market is expected to be instrumental as Helus Pharma advances its pipeline through late-stage development toward potential commercialization.
The appointment matters because it signals Helus Pharma's commitment to strengthening its leadership as it approaches critical milestones. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the FDA. It is also developing HLP004, another proprietary NSA, in Phase 2 for generalized anxiety disorder. With Durgam's guidance, Helus Pharma aims to improve the treatment landscape for depression, anxiety, and other mental health conditions through the introduction of NSAs that aim to provide durable improvements in mental health.
For investors, Durgam's appointment could be a positive signal. His track record at Intra-Cellular Therapies demonstrates a ability to achieve regulatory approvals in the competitive CNS space, which is directly relevant to Helus Pharma's own goals. As the company continues to operate in Canada, the United States, the United Kingdom, and Ireland, having a board member with such extensive experience could enhance its strategic decision-making and increase the likelihood of successful commercialization.
To view the full press release, visit https://ibn.fm/lTfIt. For more information about Helus Pharma, visit www.helus.com. The latest news and updates relating to HELP are available in the company's newsroom at Helus Pharma.
This article has been disseminated on behalf of Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP) and may include paid advertising. MissionIR, a specialized communications platform, is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets.
